Quarterly report pursuant to Section 13 or 15(d)

SHARE CAPITAL (Details Textual)

v3.10.0.1
SHARE CAPITAL (Details Textual) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Oct. 29, 2018
Jul. 20, 2018
Feb. 26, 2015
Feb. 13, 2015
Mar. 31, 2018
Dec. 31, 2018
Dec. 31, 2017
Mar. 31, 2018
Sep. 30, 2018
Jun. 12, 2018
Nov. 06, 2017
Mar. 31, 2017
Dec. 31, 2014
Loss on Mark to Market Reevaluation           $ (2,048,697) $ 0            
Stock Issued During Period, Shares, Exchangeable Shares Excercised           21,572   24,250          
Common Stock, Shares Authorized         250,000,000 500,000,000   250,000,000 500,000,000 500,000,000 250,000,000 150,000,000 200,000,000
Stock Issued During Period, Value, Conversion of Convertible Securities   $ 4,732,853     $ 9,180,785 $ 2,470,622              
Adjustments to Additional Paid in Capital, Stock Option and Warrant Reclassification         $ (2,845,557) $ 1,173,534              
Preferred Stock, Voting Rights     the Company issued one share of the Special Voting Preferred Stock, par value $0.001 per share                    
Stockholders' Equity, Reverse Stock Split the Company completed a reverse stock split and thereafter Bionik’s common stock began trading on the OTCQB market on a one-for-one hundred and fifty (1:150) split-adjusted basis.     the Company implemented a 1-for-0.831105 reverse stock split of the common stock, which had previously been approved on September 24, 2014.                  
Common Shares [Member]                          
Stock Issued During Period, Shares, Conversion of Convertible Securities           947,034              
Convertible Debt [Member]                          
Stock Issued During Period, Value, Conversion of Convertible Securities   $ 683,395                      
Convertible Debt [Member] | Common Shares [Member]                          
Stock Issued During Period, Shares, Conversion of Convertible Securities           263,639